在去年ESMO上首次公布了针对2L HER2+ mBC患者的DB-03试验的中期数据,本次会议上分析了包括OS和PFS终点在内的更新数据。 https://www.astrazeneca.com/content/dam/az/Investor_Relations/events/AstraZeneca-SABCS-2022-IR-Presentation-08-Dec-2022.pdf 该试验共入...
Phone: +41 61 688 8888 / e-mail:media.relations@roche.com Roche Investor Relations
Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-ranging push across cancer, immune-mediated, and neurological diseases.
Roche casts doubt on purchase.Daniel O'Day, head of Swiss drugmaker [ FROM PUBLISHER]Investor'sBusinessDailyEBSCO_bspInvestors Business Daily
Screen With Investor 1-Day Chart Name Price Morningstar Rating for Stocks Capital Allocation Economic Moat Market Cap Eli Lilly and Co LLY ExemplaryWide$770.7 Bil Novo Nordisk AS ADR NVO ExemplaryWide$478.1 Bil Johnson & Johnson JNJ StandardWide$368.9 Bil ...
The company strengthens the information disclosure service positively the study and the training management, the information disclosed took the inspection target, and establishes exterior feedback mechanism through the initiative disclosure information, the enhancement and investor's relation.At the[translate]...
Has four apps tailored to Core, Pathology, Molecular Labs and Point of Care Markets CE CE CE CE CE US US US EUA CE US CE US CE US Global Status RT=real time 75 Invitation to Roche Diagnostics Investor Day 2024 Innovating Diagnostics, shaping healthcare, changing lives cobas i601 mass ...
A committed investor in innovation We invest around 9 billion Swiss francs in Research and Development every year because innovation is our lifeblood. This is amongst the highest Research and Development spends in theworld across all industries. ...
the average daily trading volume in Roche ADRs exceeded 1.6 million. It should be noted that the supply of Roche ADRs is not limited to their US trading. Through J.P. Morgan, Roche’s depositary bank, registered broker-dealers can have ADRs issued or cancelled when an investor wishes to ac...
Phone: +49 172 6367262Yvette Petillon Phone: +41 79 961 92 50 Dr. Rebekka Schnell Phone: +41 79 205 27 03 Roche Investor Relations Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail:kalm.loren@gene.com Services Downloads...